NCT05115955View on ClinicalTrials.gov

PO Pain Management With Extended-release Dinalbuphine Sebacate in Patients Undergoing Arthroscopic Shoulder Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

May 31, 2024

Study Completion Date

June 30, 2024

Conditions
AnesthesiologyOrthopedic
Interventions
DRUG

DS group

In DS group, subjects will receive intramuscular single dose of NALDEBAIN® at least 12 hours before surgery.

DRUG

Control group

In Control group, subjects will receive intramuscular 2 ml sesame oil at least 12 hours before surgery.

Trial Locations (1)

114

Tri-Service General Hospital, Taipei

All Listed Sponsors
lead

Tri-Service General Hospital

OTHER

NCT05115955 - PO Pain Management With Extended-release Dinalbuphine Sebacate in Patients Undergoing Arthroscopic Shoulder Surgery | Biotech Hunter | Biotech Hunter